Deucravacitinib
-
Deucravacitinib
structure -
-
CAS No:
1609392-27-9
-
Formula:
C20H22N8O3
-
Chemical Name:
Deucravacitinib
-
Synonyms:
Tyk2-IN-4;TYK2-IN-4;BMS986165;BMS-986165;BMS 986165;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Deucravacitinib;Deucravacitinib(BMS986165);Deucravacitinib (TYK2-IN-4;6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide;DeucravacitinibQ: What is Deucravacitinib Q: What is the CAS Number of Deucravacitinib
- Categories:
-
CAS No:
Description
Deucravacitinib (trade name Sotykto) is a first-in-class tyrosine kinase 2 (TYK2) inhibitor recently approved for the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic inflammatory skin disease characterized by the formation of red patches and scaling on the skin. Discovered by Bristol Myers Squibb (BMS), deuterated colestitinib, also known as BMS-986165, is the first JAK inhibitor containing deuterium and the first approved selective TYK2 inhibitor, showing more than 50,000-fold selectivity over JAK1, JAK2 and JAK3.
Deucravacitinib, a highly selective allosteric TYK2 inhibitor, received its first approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy protein and lipid kinases and pseudokinases with the exception of BMPR2 (IC50 = 193 nM) and JAK1 JH2 pseudokinase domain (IC50 = 1 nM). Despite its potent affinity for JAK1 JH2, deucravacitinib elicited low functional activity in a JAK1/JAK3-dependent IL-2 stimulated cellular assay. BMS-986202 displays >10,000-fold selectivity for TYK2 JH2 over a diverse panel of 273 kinases and pseudokinases that include JAK family members. Like deucravacitinib, its high binding affinity to JAK1 JH2 (IC50 = 7.8 nM) did not translate to functional activity in the cellular assay.
Drug Information
Treatment of psoriasis
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)|Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
BMS-986165
Deucravacitinib Use and Manufacturing
BMS-986165 is a novel oral selective TYK2 inhibitor with a unique mechanism of action that is expected to provide a promising oral option to help patients effectively manage their psoriasis.
Deucravacitinib is a tyrosine kinase 2 inhibitor which can be useful in the treatment of systemic lupus erythematosus.
Human Drugs -> EU pediatric investigation plans
Recommended Suppliers of Deucravacitinib
-
![China]()
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
![China]()
CN
1 YR
Business licensedTrader Supplier of 3-(1-Naphthoyl)indoleInquiryCAS No.: 1609392-27-9Grade: Pharmaceutical GradeContent: 99% -
![China]()
CN
3 YRS
Business licensedTrader Supplier of Herbal extract,Nutritions,Food additives,API,Intermediates -
![China]()
CN
3 YRS
Business licensedTrader Supplier of Upadacitinib Hemihydrate,(S)-(+)-1-Boc-3-hydroxypyrrolidine -
![China]()
CN
3 YRS
Business licensed Certified factoryManufactory Supplier of Dyes,Textile agent,Medical intermediate,API,Pigments,Basic Chemicals
Learn More Other Chemicals
-
Miconazole nitrate
22832-87-7
-
Miconazole
22916-47-8
-
Clotrimazole
23593-75-1
-
Econazole nitrate Formula
24169-02-6
-
Gemfibrozil Formula
25812-30-0
-
Econazole Formula
27220-47-9
-
(±)-Bupropion Structure
34911-55-2
-
6H,7H-[1]Benzopyrano[4,3-b][1]benzopyran-6,7-dione Structure
38210-27-4
-
What is Fluoxetine
54910-89-3
-
What is Selumetinib
606143-52-6